| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.09 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.098 | 0.09 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.09 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.089 | 0.1 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.056 | 0.1 |